Skip to main content
. 2021 Feb 22;15:721–733. doi: 10.2147/DDDT.S288859

Figure 4.

Figure 4

Analyses of discontinuation of two miRNA-based clinical projects. (A and B) Enrichment for targets of MRX34 in terms of enrichment score and number of genes. (C) Unapproved and approved targets number of MRX34 validated targets in the immune system and cytokine signaling in the immune system. (D and E) Enrichment for targets of miR-122 (drug RG-101) in terms of enrichment score and number of genes.